Identification of an Innate Immune-Related Prognostic Signature in Early-Stage Lung Squamous Cell Carcinoma

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Zappa C, Mousa SA. Non-small cell lung cancer: current treatment and future advances. Transl Lung Cancer Res. 2016;5(3):288–300. doi:10.21037/tlcr.2016.06.07
   PubMed Web of Science ®Google Scholar
• Yuan H, Liu J, Zhang J. The current landscape of immune checkpoint blockade in metastatic lung squamous cell carcinoma. Molecules. 2021;26(5):1392. doi:10.3390/molecules26051392
   PubMed Web of Science ®Google Scholar
• Socinski MA, Obasaju C, Gandara D, et al. Current and emergent therapy options for advanced squamous cell lung cancer. J Thorac Oncol. 2018;13(2):165–183. doi:10.1016/j.jtho.2017.11.111
   PubMed Web of Science ®Google Scholar
• Hirsch FR, Spreafico A, Novello S, Wood MD, Simms L, Papotti M. The prognostic and predictive role of histology in advanced non-small cell lung cancer: a literature review. J Thorac Oncol. 2008;3(12):1468–1481. doi:10.1097/JTO.0b013e318189f551
   PubMed Web of Science ®Google Scholar
• Nichols L, Saunders R, Knollmann FD. Causes of death of patients with lung cancer. Arch Pathol Lab Med. 2012;136(12):1552–1557. doi:10.5858/arpa.2011-0521-OA
   PubMed Web of Science ®Google Scholar
• Lazzari C, Karachaliou N, Gregorc V, et al. Second-line therapy of squamous non-small cell lung cancer: an evolving landscape. Expert Rev Respir Med. 2017;11(6):469–479. doi:10.1080/17476348.2017.1326822
   PubMed Web of Science ®Google Scholar
• Cui J, Chen Y, Wang HY, Wang RF. Mechanisms and pathways of innate immune activation and regulation in health and cancer. Hum Vaccin Immunother. 2014;10(11):3270–3285. doi:10.4161/21645515.2014.979640
   PubMed Web of Science ®Google Scholar
• Takeda K, Akira S. Toll-like receptors in innate immunity. Int Immunol. 2005;17(1):1–14. doi:10.1093/intimm/dxh186
   PubMed Web of Science ®Google Scholar
• Hinshaw DC, Shevde LA. The tumor microenvironment innately modulates cancer progression. Cancer Res. 2019;79(18):4557–4566. doi:10.1158/0008-5472.CAN-18-3962
   PubMed Web of Science ®Google Scholar
• Zhou F, Qiao M, Zhou C. The cutting-edge progress of immune-checkpoint blockade in lung cancer. Cell Mol Immunol. 2021;18(2):279–293. doi:10.1038/s41423-020-00577-5
   PubMed Web of Science ®Google Scholar
• Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375(19):1823–1833. doi:10.1056/NEJMoa1606774
   PubMed Web of Science ®Google Scholar
• Herbst RS, Giaccone G, de Marinis F, et al. Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC. N Engl J Med. 2020;383(14):1328–1339. doi:10.1056/NEJMoa1917346
   PubMed Web of Science ®Google Scholar
• Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEY-NOTE-010): a randomised controlled trial. Lancet. 2016;387(10027):1540–1550. doi:10.1016/S0140-6736(15)01281-7
   PubMed Web of Science ®Google Scholar
• Doroshow DB, Sanmamed MF, Hastings K, et al. Immunotherapy in non-small cell lung cancer: facts and hopes. Clin Cancer Res. 2019;25(15):4592–4602. doi:10.1158/1078-0432.CCR-18-1538
   PubMed Web of Science ®Google Scholar
• Chi A, He X, Hou L, et al. Classification of non-small cell lung cancer’s tumor immune micro-environment and strategies to augment its response to immune checkpoint blockade. Cancers (Basel). 2021;13(12):2924. doi:10.3390/cancers13122924
   PubMed Web of Science ®Google Scholar
• Lentz RW, Colton MD, Mitra SS, Messersmith WA. Innate immune checkpoint inhibitors: the next breakthrough in medical oncology? Mol Cancer Ther. 2021;20(6):961–974. doi:10.1158/1535-7163.MCT-21-0041
   PubMed Web of Science ®Google Scholar
• Talty R, Olino K. Metabolism of innate immune cells in cancer. Cancers (Basel). 2021;13(4):904. doi:10.3390/cancers13040904
   PubMed Web of Science ®Google Scholar
• Sun R, Li S, Zhao K, Diao M, Li L. Identification of ten core hub genes as potential biomarkers and treatment target for hepatoblastoma. Front Oncol. 2021;11:591507. doi:10.3389/fonc.2021.591507
   PubMed Web of Science ®Google Scholar
• Zhang F, Liu Y, Yang Y, Yang K. Development and validation of a fourteen- innate immunity-related gene pairs signature for predicting prognosis head and neck squamous cell carcinoma. BMC Cancer. 2020;20(1):1015. doi:10.1186/s12885-020-07489-7
   PubMed Web of Science ®Google Scholar
• Zhang B, Nie X, Miao X, Wang S, Li J, Wang S. Development and verification of an immune-related gene pairs prognostic signature in ovarian cancer. J Cell Mol Med. 2021;25(6):2918–2930. doi:10.1111/jcmm.16327
   PubMed Web of Science ®Google Scholar
• Ma XB, Xu YY, Zhu MX, Wang L. Prognostic signatures based on thirteen immune-related genes in colorectal cancer. Front Oncol. 2021;10:591739. doi:10.3389/fonc.2020.591739
   PubMed Web of Science ®Google Scholar
• Bueno R, Richards WG, Harpole DH, et al. Multi-institutional prospective validation of prognostic mRNA signatures in early stage squamous lung cancer (Alliance). J Thorac Oncol. 2020;15(11):1748–1757. doi:10.1016/j.jtho.2020.07.005
   PubMed Web of Science ®Google Scholar
• Friedman J, Hastie T, Tibshirani R. Regularization paths for generalized linear models via coordinate descent. J Stat Softw. 2010;33(1):1–22. doi:10.18637/jss.v033.i01
   PubMed Web of Science ®Google Scholar
• Vickers AJ, Cronin AM, Elkin EB, Gonen M. Extensions to decision curve analysis, a novel method for evaluating diagnostic tests, prediction models and molecular markers. BMC Med Inform Decis Mak. 2008;8:53. doi:10.1186/1472-6947-8-53
   PubMed Web of Science ®Google Scholar
• Yu G, Wang LG, Han Y, He QY. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012;16(5):284–287. doi:10.1089/omi.2011.0118
   PubMed Web of Science ®Google Scholar
• Newman AM, Steen CB, Liu CL, et al. Determining cell type abundance and expression from bulk tissues with digital cytometry. Nat Biotechnol. 2019;37(7):773–782. doi:10.1038/s41587-019-0114-2
   PubMed Web of Science ®Google Scholar
• Li X, Wu JB, Li Q, Shigemura K, Chung LW, Huang WC. SREBP-2 promotes stem cell-like properties and metastasis by transcriptional activation of c-Myc in prostate cancer. Oncotarget. 2016;7(11):12869–12884. doi:10.18632/oncotarget.7331
   PubMedGoogle Scholar
• Zhong C, Fan L, Li Z, Yao F, Zhao H. SREBP2 is upregulated in esophageal squamous cell carcinoma and co-operates with c-Myc to regulate HMGCR expression. Mol Med Rep. 2019;20(4):3003–3010. doi:10.3892/mmr.2019.10577
   PubMed Web of Science ®Google Scholar
• Wang Q, Zeng F, Sun Y, et al. Etk interaction with PFKFB4 modulates chemoresistance of small-cell lung cancer by regulating autophagy. Clin Cancer Res. 2018;24(4):950–962. doi:10.1158/1078-0432.CCR-17-1475
   PubMed Web of Science ®Google Scholar
• Tu T, Thotala D, Geng L, Hallahan DE, Willey CD. Bone marrow X kinase-mediated signal transduction in irradiated vascular endothelium. Cancer Res. 2008;68(8):2861–2869. Erratum in: Cancer Res. 2008;68(19):8189. doi:10.1158/0008-5472.CAN-07-5743
   PubMed Web of Science ®Google Scholar
• Yun JW, Lee S, Ryu D, et al. Biomarkers associated with tumor heterogeneity in prostate cancer. Transl Oncol. 2019;12(1):43–48. doi:10.1016/j.tranon.2018.09.003
   PubMed Web of Science ®Google Scholar
• Sébert M, Passet M, Raimbault A, et al. Germline DDX41 mutations define a significant entity within adult MDS/AML patients. Blood. 2019;134(17):1441–1444. doi:10.1182/blood.2019000909
   PubMed Web of Science ®Google Scholar
• Polprasert C, Schulze I, Sekeres MA, et al. Inherited and somatic defects in DDX41 in myeloid neoplasms. Cancer Cell. 2015;27(5):658–670. doi:10.1016/j.ccell.2015.03.017
   PubMed Web of Science ®Google Scholar
• Qin K, Jian D, Xue Y, et al. DDX41 regulates the expression and alternative splicing of genes involved in tumorigenesis and immune response. Oncol Rep. 2021;45(3):1213–1225. doi:10.3892/or.2021.7951
   PubMed Web of Science ®Google Scholar
• Wu Y, Ni H, Yang D, et al. Driver and novel genes correlated with metastasis of non-small cell lung cancer: a comprehensive analysis. Pathol Res Pract. 2021;224:153551. doi:10.1016/j.prp.2021.153551
   PubMed Web of Science ®Google Scholar
• Dong J, Jin G, Wu C, et al. Genome-wide association study identifies a novel susceptibility locus at 12q23.1 for lung squamous cell carcinoma in Han Chinese. PLoS Genet. 2013;9(1):e1003190. doi:10.1371/journal.pgen.1003190
   PubMed Web of Science ®Google Scholar
• Yu J, Li S, Guo J, Xu Z, Zheng J, Sun X. Farnesoid X receptor antagonizes Wnt/β-catenin signaling in colorectal tumorigenesis. Cell Death Dis. 2020;11(8):640. doi:10.1038/s41419-020-02819-w
   PubMed Web of Science ®Google Scholar
• Lee YJ, Lee EY, Choi BH, Jang H, Myung JK, You HJ. The role of nuclear receptor subfamily 1 group H member 4 (NR1H4) in colon cancer cell survival through the regulation of c-Myc stability. Mol Cells. 2020;43(5):459–468. doi:10.14348/molcells.2020.0041
   PubMed Web of Science ®Google Scholar
• Ohara N, Haraguchi N, Koseki J, et al. Low expression of the GOPC is a poor prognostic marker in colorectal cancer. Oncol Lett. 2017;14(4):4483–4490. doi:10.3892/ol.2017.6817
   PubMed Web of Science ®Google Scholar
• Spangler JB, Moraga I, Mendoza JL, Garcia KC. Insights into cytokine-receptor interactions from cytokine engineering. Annu Rev Immunol. 2015;33:139–167. doi:10.1146/annurev-immunol-032713-120211
   PubMed Web of Science ®Google Scholar
• Mollica Poeta V, Massara M, Capucetti A, Bonecchi R. Chemokines and chemokine receptors: new targets for cancer immunotherapy. Front Immunol. 2019;10:379. doi:10.3389/fimmu.2019.00379
   PubMed Web of Science ®Google Scholar
• Thorsson V, Gibbs DL, Brown SD, et al. The immune landscape of cancer. Immunity. 2018;48(4):812–830. Erratum in: Immunity. 2019;51(2):411–412. doi:10.1016/j.immuni.2018.03.023
   PubMed Web of Science ®Google Scholar
• Demers M, Wong SL, Martinod K, et al. Priming of neutrophils toward NETosis promotes tumor growth. Oncoimmunology. 2016;5(5):e1134073. doi:10.1080/2162402X.2015.1134073
   PubMed Web of Science ®Google Scholar
• He M, Peng A, Huang XZ, et al. Peritumoral stromal neutrophils are essential for c-Met-elicited metastasis in human hepatocellular carcinoma. Oncoimmunology. 2016;5(10):e1219828. doi:10.1080/2162402X.2016.1219828
   PubMed Web of Science ®Google Scholar
• Mascaux C, Angelova M, Vasaturo A, et al. Immune evasion before tumour invasion in early lung squamous carcinogenesis. Nature. 2019;571(7766):570–575. doi:10.1038/s41586-019-1330-0
   PubMed Web of Science ®Google Scholar
• Chen H, Zou M, Teng D, Hu Y, Zhang J, He W. Profiling the pattern of the human T-cell receptor γδ complementary determinant region 3 repertoire in patients with lung carcinoma via high-throughput sequencing analysis. Cell Mol Immunol. 2019;16(3):250–259.
   PubMed Web of Science ®Google Scholar
• Kakimi K, Matsushita H, Murakawa T, Nakajima J. γδ T cell therapy for the treatment of non-small cell lung cancer. Transl Lung Cancer Res. 2014;3(1):23–33. doi:10.3978/j.issn.2218-6751.2013.11.01
   PubMedGoogle Scholar
• Platonova S, Cherfils-Vicini J, Damotte D, et al. Profound coordinated alterations of intratumoral NK cell phenotype and function in lung carcinoma. Cancer Res. 2011;71(16):5412–5422. doi:10.1158/0008-5472.CAN-10-4179
   PubMed Web of Science ®Google Scholar
• Cong J, Wei H. Natural killer cells in the lungs. Front Immunol. 2019;10:1416. doi:10.3389/fimmu.2019.01416
   PubMed Web of Science ®Google Scholar
• Varricchi G, Galdiero MR, Loffredo S, et al. Are mast cells MASTers in cancer? Front Immunol. 2017;8:424. doi:10.3389/fimmu.2017.00424
   PubMed Web of Science ®Google Scholar
• Shikotra A, Ohri CM, Green RH, Waller DA, Bradding P. Mast cell phenotype, TNFα expression and degranulation status in non-small cell lung cancer. Sci Rep. 2016;6:38352. doi:10.1038/srep38352
   PubMed Web of Science ®Google Scholar